A special partnership between UCL and a Japanese pharmaceutical firm which is investigating new treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s has been extended to 2030. University College London (UCL) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) have signed a new agreement to extend their long-standing collaboration in drug discovery and development for five more years, taking the partnership through to 2030. This alliance reinforces a unique model